We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access
Read MoreHide Full Article
Key Takeaways
MiniMed Flex is now available to Medicare and Medicare Advantage beneficiaries across the United States.
SmartGuard adjusts insulin delivery every five minutes to simplify diabetes management day and night.
Flex is half the size of prior pumps, holds 300 insulin units and will add Abbott sensor compatibility.
MiniMed Group, Inc. (MMED - Free Report) recently announced that the MiniMed Flex system is now available to Medicare and Medicare Advantage beneficiaries in the United States. The system was commercially rolled out in the United States for commercially insured and private-pay patients in March. The expanded coverage broadens access to the company’s smallest and only app-controlled insulin pump, enabling more people living with diabetes to benefit from its automated insulin delivery technology. Powered by the SmartGuard algorithm, the MiniMed Flex system is designed to simplify diabetes management by automatically adjusting insulin delivery every five minutes.
Per management, Medicare coverage for MiniMed Flex reflects the company's commitment to making advanced diabetes technology available to a broader population. MMED believes diabetes management is a continuous challenge and that eligible beneficiaries, regardless of age, should have access to tools that seamlessly fit into everyday life while helping reduce the overall burden of care.
Likely Trend of MMED Stock Following the News
MMED stock has gained 3.1% since the announcement on Wednesday. Year to date, shares of the company have lost 9% compared with the industry’s 1.4% fall. However, the S&P 500 has risen 7.5% during the same timeframe.
Medicare coverage is likely to strengthen MMED’s long-term growth prospects by increasing the addressable market for the MiniMed Flex platform. Broader reimbursement should support higher adoption among eligible beneficiaries while reinforcing recurring revenue opportunities from the company’s diabetes management ecosystem. Leveraging the proven SmartGuard technology behind the MiniMed 780G system enhances the platform’s credibility and could improve customer confidence. The announcement positions MiniMed to further strengthen its presence in the automated insulin delivery market as it continues to expand sensor compatibility.
MMED currently has a market capitalization of $4.73 billion.
Image Source: Zacks Investment Research
More on the News
MiniMed Flex is approximately half the size of the company’s previous insulin pumps, while still accommodating up to 300 units of insulin. Its compact design, combined with smartphone-based control, allows users to manage therapy with greater discretion and convenience. The system incorporates the same SmartGuard algorithm used in the MiniMed 780G platform, automatically adjusting insulin delivery every five minutes throughout the day and night to help optimize glucose management.
The expanded Medicare availability is supported by encouraging real-world evidence presented at the 86th American Diabetes Association Scientific Sessions. Data showed that Medicare beneficiaries using the MiniMed 780G system achieved glucose control outcomes that exceeded the American Diabetes Association’s recommended glycemic targets, reinforcing the effectiveness of the SmartGuard technology now available through MiniMed Flex.
At present, the MiniMed Flex system is offered in the United States with Medtronics’ Simplera Sync sensor. The company also plans to introduce compatibility with Abbott Laboratories' Instinct sensor later this summer, providing users with additional sensor options while expanding the platform’s flexibility.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin delivery devices market size was estimated at $19.3 billion in 2025 and is expected to reach $35.2 billion by 2033, expanding at a CAGR of 7.8% from 2026 to 2033.
Growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.
Other News
In June, MMED commercially launched the MiniMed 780G automated insulin delivery system integrated with Abbott Laboratories' Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor across Europe. The rollout expands the company's sensor portfolio in the region and provides people with diabetes with greater flexibility and choice in managing their condition.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
View the Zacks #1 Rank List
Image: Bigstock
MMED Gets Medicare Coverage for Flex and Broadens Diabetes Care Access
Key Takeaways
MiniMed Group, Inc. (MMED - Free Report) recently announced that the MiniMed Flex system is now available to Medicare and Medicare Advantage beneficiaries in the United States. The system was commercially rolled out in the United States for commercially insured and private-pay patients in March. The expanded coverage broadens access to the company’s smallest and only app-controlled insulin pump, enabling more people living with diabetes to benefit from its automated insulin delivery technology. Powered by the SmartGuard algorithm, the MiniMed Flex system is designed to simplify diabetes management by automatically adjusting insulin delivery every five minutes.
Per management, Medicare coverage for MiniMed Flex reflects the company's commitment to making advanced diabetes technology available to a broader population. MMED believes diabetes management is a continuous challenge and that eligible beneficiaries, regardless of age, should have access to tools that seamlessly fit into everyday life while helping reduce the overall burden of care.
Likely Trend of MMED Stock Following the News
MMED stock has gained 3.1% since the announcement on Wednesday. Year to date, shares of the company have lost 9% compared with the industry’s 1.4% fall. However, the S&P 500 has risen 7.5% during the same timeframe.
Medicare coverage is likely to strengthen MMED’s long-term growth prospects by increasing the addressable market for the MiniMed Flex platform. Broader reimbursement should support higher adoption among eligible beneficiaries while reinforcing recurring revenue opportunities from the company’s diabetes management ecosystem. Leveraging the proven SmartGuard technology behind the MiniMed 780G system enhances the platform’s credibility and could improve customer confidence. The announcement positions MiniMed to further strengthen its presence in the automated insulin delivery market as it continues to expand sensor compatibility.
MMED currently has a market capitalization of $4.73 billion.
Image Source: Zacks Investment Research
More on the News
MiniMed Flex is approximately half the size of the company’s previous insulin pumps, while still accommodating up to 300 units of insulin. Its compact design, combined with smartphone-based control, allows users to manage therapy with greater discretion and convenience. The system incorporates the same SmartGuard algorithm used in the MiniMed 780G platform, automatically adjusting insulin delivery every five minutes throughout the day and night to help optimize glucose management.
The expanded Medicare availability is supported by encouraging real-world evidence presented at the 86th American Diabetes Association Scientific Sessions. Data showed that Medicare beneficiaries using the MiniMed 780G system achieved glucose control outcomes that exceeded the American Diabetes Association’s recommended glycemic targets, reinforcing the effectiveness of the SmartGuard technology now available through MiniMed Flex.
At present, the MiniMed Flex system is offered in the United States with Medtronics’ Simplera Sync sensor. The company also plans to introduce compatibility with Abbott Laboratories' Instinct sensor later this summer, providing users with additional sensor options while expanding the platform’s flexibility.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global insulin delivery devices market size was estimated at $19.3 billion in 2025 and is expected to reach $35.2 billion by 2033, expanding at a CAGR of 7.8% from 2026 to 2033.
Growth is largely attributed to the rising global prevalence of diabetes, which has heightened the demand for advanced and user-friendly solutions for diabetes management.
Other News
In June, MMED commercially launched the MiniMed 780G automated insulin delivery system integrated with Abbott Laboratories' Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor across Europe. The rollout expands the company's sensor portfolio in the region and provides people with diabetes with greater flexibility and choice in managing their condition.
MiniMed Group, Inc. Price
MiniMed Group, Inc. price | MiniMed Group, Inc. Quote
MMED’s Zacks Rank & Key Picks
Currently, MMED carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , McKesson (MCK - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
West Pharmaceutical reported second-quarter 2026 adjusted earnings per share (EPS) of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
McKesson reported a fourth-quarter fiscal 2026 adjusted EPS of $11.69, which beat the Zacks Consensus Estimate by 1.1%. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%.
McKesson has an estimated long-term earnings growth rate of 13.7%. MCK’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.
Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%.
Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.